Table 3:
Tumor and Treatment Characteristics
| Factor | NHW N = 1,615 27.3% |
NHB N = 1,060 17.9% |
Hispanic N = 3,234 54.7% |
All N = 5,909 |
p-value |
|---|---|---|---|---|---|
| Clinical Stage | <0.001 | ||||
| I | 749 (46.4) | 280 (26.4) | 1,165 (36.0) | 2,194 (37.1) | |
| II | 503 (31.1) | 379 (35.8) | 1,158 (35.8) | 2,040 (34.5) | |
| III | 206 (12.8) | 220 (20.8) | 587 (18.2) | 1,013 (17.1) | |
| IV | 120 (7.4) | 141 (13.3) | 240 (7.4) | 501 (8.5) | |
| Unknown | 37 (2.3) | 40 (3.8) | 84 (2.6) | 161 (2.7) | |
| Tumor Grade | <0.001 | ||||
| Well diff./Moderately (0) | 1,025 (63.5) | 499 (47.1) | 1,931 (59.7) | 3,455 (58.5) | |
| Poorly diff. (1) | 583 (36.1) | 541 (51.0) | 1,282 (39.6) | 2,406 (40.7) | |
| Anaplastic/Undifferentiated | 7 ( 0.4) | 20 ( 1.9) | 21 (0.6) | 48 (0.8) | |
| Receptor Status | <0.001 | ||||
| ER+/HER2− | 1,026 (63.5) | 502 (47.4) | 1,992 (61.6) | 3,520 (59.6) | |
| ER+/HER2+ | 169 (10.5) | 107 (10.1) | 345 (10.9) | 639 (10.5) | |
| ER-/HER2+ | 83 ( 5.1) | 101 ( 9.5) | 244 (7.5) | 428 (7.2) | |
| ER-/HER2− | 194 (12.0) | 283 (26.7) | 467 (14.4) | 944 (16.0) | |
| Unknown | 143 (8.9) | 67 (6.3) | 177 (5.5) | 387 (6.5) | |
| Pathologic Stage | <0.001 | ||||
| I | 746 (46.2) | 280 (26.4) | 1,117 (34.5) | 2,143 (36.3) | |
| II | 398 (24.6) | 264 (24.9) | 885 (27.4) | 1,547 (26.2) | |
| III | 143 ( 8.9) | 105 ( 9.9) | 352 (10.9) | 600 (10.2) | |
| IV | 42 ( 2.6) | 37 ( 3.5) | 90 (2.8) | 169 (2.9) | |
| Unknown | 272 (16.8) | 368 (34.7) | 767 (23.7) | 1,407 (23.8) | |
| Treatment | <0.001 | ||||
| Surgery | 1,422(88.0) | 732 (69.1) | 2,608 (80.6) | 4,762 (80.6) | |
| Chemotherapy | 818 (50.7) | 626 (59.1) | 1,885 (58.3) | 3,329 (56.3) | |
| Radiation | 769 (47.6) | 418 (39.4) | 1,528 (47.2) | 2,715 (45.9) | |
| Endocrine Therapy | 1,054 (65.3) | 434 (40.9) | 1,832 (56.6) | 3,320 (56.2) | |
| NCCN Guideline Based Treatment | 1,285 (81.4) | 739 (72.5) | 2,443 (77.6) | 4,467 (77.7) | <0.001 |